Results 141 to 150 of about 27,541,156 (167)

Identifying novel inhibitors targeting Exportin-1 for the potential treatment of COVID-19

Archives of Microbiology
The nuclear export protein 1 (XPO1) mediates the nucleocytoplasmic transport of proteins and ribonucleic acids (RNAs) and plays a prominent role in maintaining cellular homeostasis. XPO1 has emerged as a promising therapeutic approach to interfere with the lifecycle of many viruses.
Tanuj Sharma, Tanmoy Mondal, Sajid A. Khan, Marianela Patzi Churqui, Kristina Nyström, Ketan Thombare, M. H. Baig, Jae-June Dong   +7 more
semanticscholar   +3 more sources

Abstract 6909: Exportin 1 as a novel therapeutic target in gastroenteropancreatic neuroendocrine tumors

Cancer Research
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show minimal response to FDA-approved therapies suggesting an urgent need for the identification of novel and effective therapeutic targets. Aberrant nuclear protein transport to the cytoplasm,
Md. Hafiz Uddin, H. Khan, A. Aboukameel, Sahar F. Bannoura, Hugo Jimenez, Grayson Barker, Allan M. Johansen, K. Choucair, S. Jaiman, G. Dyson, Yang Shi, M. A. Al Hallak, N. Vaishampayan, Steve H Kim, Eliza W. Beal, M. Tobon, Herbert Chen, M. W. Saif, Jennifer Beebe-Dimmer, A. Shields, R. Mohammad, P. Philip, B. El-Rayes, B. Pasche, A. Azmi   +24 more
semanticscholar   +1 more source

Exportin-1 (XPO1, CRM1) inhibitors for the management of viral infection

Drugs of the Future, 2021
A therapeutic gap exists between new emerging infectious diseases and effective treatments. Targeting host factors involved in the replication strategies of evolutionarily diverse viruses may bridge this gap. Exportin-1 (XPO1, also termed chromosome region maintenance 1 [CRM1]) is a cellular nuclear export receptor for cellular and viral protein and ...
openaire   +1 more source

Inhibition of Exportin-1 inhibits endothelial cell ICAM expression

Journal of the American College of Surgeons, 2004
Abstract Introduction: Regulation of the export of adaptor proteins that reside in the nucleus may modulate signal transduction. MyD88 is the principal adaptor protein for Toll/IL-1 receptor signaling. We have observed that MyD88 is a predominantly nuclear protein in murine macrophages.
Mark D. Walsh, Anirban Banerjee, Christine Hamiel, Katherine Barsness, Robert McIntyre   +4 more
openaire   +1 more source

EXPORTIN 1 INHIBITION ATTENUATES NUCLEAR FACTOR-κB-DEPENDENT GENE EXPRESSION

Shock, 2008
Activation of nuclear factor (NF)-kappaB is mediated by signal-induced phosphorylation of IkappaBalpha, subsequent IkappaBalpha degradation, and then translocation of unbound NF-kappaB to the nucleus. Termination of gene expression occurs when IkappaBalpha binds NF-kappaB subunits (Rel A) in the nucleus.
Mark D, Walsh, Christine R, Hamiel, Anirban, Banerjee, Aaron M, Cheng, Guillermo, Escobar, Robert C, McIntyre   +5 more
openaire   +2 more sources

Tackling the Moving Mutant Target: Taxifolin Derivatives as Novel Putative E571K Exportin-1 Inhibitors for KRAS-mutant Lung Adenocarcinoma

2024 International Conference on Science, Engineering and Business for Driving Sustainable Development Goals (SEB4SDG)
Introduction: The association between drug resistance and genomic mutations underscores their clinical importance in cancer treatment strategies. One such mutation is the E571K alteration in the exportin-1 gene (XPO1), which affects nuclear export ...
T. Adigun, O. Alejolowo, F. Sulaiman, I. A. Oluwadare, O. Ogunro, A. Akinduko, I. Evbuomwan, A. Agunlejika, C. Nwonuma, D. Rotimi   +9 more
semanticscholar   +1 more source

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

Gynecologic Oncology, 2020
Selinexor is an oral inhibitor of the nuclear export protein Exportin 1 (XPO1) with demonstrated antitumor activity in solid and hematological malignancies. We evaluated the efficacy and safety of selinexor in heavily pretreated, recurrent gynecological malignancies.In this phase 2 trial, patients received selinexor (35 or 50 mg/m2 twice-weekly [BIW ...
Vergote, I. B., Lund, B., Peen, U., Umajuridze, Z., Mau-Sorensen, M., Kranich, A., Van Nieuwenhuysen, E., Haslund, C., Nottrup, T., Han, S. N., Concin, N., Unger, T. J., Chai, Y., Au, N., Rashal, T., Joshi, A., Crochiere, M., Landesman, Y., Shah, J., Shacham, S., Kauffman, M., Mirza, M. R.   +21 more
openaire   +4 more sources

Abstract 5734: Targeting exportin 1 reduces cutaneous squamous cell carcinoma growth alone and in combination with 5-fluorouracil

Cancer Research
Cutaneous squamous cell carcinoma (cSCC) affects approximately 1.8 million people annually in the US with an increasing number of cases. Nuclear-cytoplasmic transport of proteins and RNA is vital for cellular homeostasis and becomes dysregulated in
Moynul Islam, J. Rudd, L. Monga, J. Grunkemeyer, Laura A. Hansen   +4 more
semanticscholar   +1 more source

Selinexor. Exportin-1 (XPO1) inhibitor, Oncolytic

Drugs of the Future, 2014
null Riaz, W., null Burke, N., null Mahipal, A.   +2 more
openaire   +1 more source

INHIBITION OF EXPORTIN-1 DISRUPTS MYD88 DEPENDENT SIGNALING.

Shock, 2004
M. D. Walsh, K. A. Barsness, J. Y. Cha, J. H. Clarke, A. Banerjee, R. C. McIntyre   +5 more
openaire   +1 more source